TABLE 4.
Studies that assessed risk of Alzheimer disease according to the TCN2 rs1801198 (c.776G>C) polymorphism1
| Cases, n |
Controls, n |
||||||
| Reference | STREGA score | Country (ethnicity) | Study design | Total | CC/CG/GG | Total | CC/CG/GG |
| McCaddon et al., 2004 (30)2 | 12 of 19 | United Kingdom (Caucasians) | Case-control | 65 | 16/34/15 | 71 | 26/36/9 |
| McCaddon et al., 2004 (30)3 | 12 of 19 | United Kingdom (Caucasians) | Case-control | 94 | 32/45/17 | 107 | 42/50/15 |
| Cascalheira et al., 2015 (58) | 11 of 19 | Portugal (Caucasians) | Case-control | 26 | 11/8/7 | 28 | 4/17/7 |
1
STREGA, Strengthening the Reporting of Genetic Association; TCN2, transcobalamin 2.
2
Clinical series.
3
Histopathologic series.